

## Extended-release niacin lowers ApoB-48 concentration in T2DM

January 11 2016



(HealthDay)—For patients with type 2 diabetes, a statin plus extended-



release niacin (ERN) lowers apolipoprotein B-48 (apoB-48) concentration compared to a statin alone, according to a study published online Dec. 18 in *Diabetes, Obesity and Metabolism*.

Jing Pang, from the University of Western Australia in Perth, and colleagues examined the effect of ERN on apoB-48 kinetics in 12 statin-treated men with type 2 diabetes. Participants were randomly allocated to receive 12 weeks of rosuvastatin (R) or R plus ERN and then crossed over to the alternative treatment. At the end of each treatment period, postprandial metabolic studies were performed and apoB-48 kinetics were determined.

The researchers found that the apoB-48 concentration was lower with ERN versus statin alone (P = 0.03). ERN treatment also correlated with significantly lower postprandial triglyceride and apoB-48 area under the curve (AUC; P treatment was associated with lower apoB-48 secretion rate (SR) in the basal state (P = 0.04) and a lower number of apoB-48 containing particles secreted in response to fat load (P = 0.02). ERN was not associated with alteration in apoB-48 fractional catabolic rates (P = 0.79).

"ERN reduces apoB-48 concentration by lowering fasting and postprandial apoB-48 SR," the authors write. "This effect may be beneficial for lowering atherogenic postprandial lipoproteins and may provide <u>cardiovascular disease risk</u> benefit in patients with type 2 <u>diabetes</u>."

One author disclosed financial ties to Abbott, which provided the ERN for the study.

**More information:** Abstract

Full Text (subscription or payment may be required)



## Copyright © 2016 HealthDay. All rights reserved.

Citation: Extended-release niacin lowers ApoB-48 concentration in T2DM (2016, January 11) retrieved 6 May 2024 from

https://medicalxpress.com/news/2016-01-extended-release-niacin-lowers-apob-t2dm.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.